Afsaneh Rajizadeh1, Hassan Mozaffari-Khosravi2, Mojtaba Yassini-Ardakani3, Ali Dehghani4. 1. Department of Nutrition, Faculty of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 2. Department of Nutrition, Faculty of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Electronic address: Mozaffari.kh@gmail.com. 3. Department of General Psychiatry, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 4. Department of Biostatistics and Epidemiology, Faculty of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Abstract
OBJECTIVES: The aim of this study was to determine the effect of magnesium supplementation on the depression status of depressed patients suffering from magnesium deficiency. METHODS:Sixty depressed people suffering from hypomagnesemia participated in this trial. The individuals were randomly categorized into two groups of 30 members; one receiving two 250-mg tablets of magnesium oxide (MG) daily and the other receiving placebo (PG) for 8 wk. The Beck Depression Inventory-II was conducted and the concentration of serum magnesium was measured. RESULTS: At the end of intervention, 88.5% of the MG and 48.1% of the PG (P = 0.002) had a normal level of magnesium. The mean changes of serum magnesium were significantly different across the two groups. After the intervention, the mean Beck score significantly declined. However, in the MG, this reduction was more significant than in the PG (P = 0.02), so that the mean changes in this group experienced 15.65 ± 8.9 reduction, but in the PG, it declined by 10.40 ± 7.9. CONCLUSIONS: Daily consumption of 500 mg magnesium oxide tablets for ≥8 wk by depressed patients suffering from magnesium deficiency leads to improvements in depression status and magnesium levels. Therefore, assessment of the magnesium serum and resolving this deficiency positively influence the treatment of depressed patients.
RCT Entities:
OBJECTIVES: The aim of this study was to determine the effect of magnesium supplementation on the depression status of depressedpatients suffering from magnesium deficiency. METHODS: Sixty depressedpeople suffering from hypomagnesemia participated in this trial. The individuals were randomly categorized into two groups of 30 members; one receiving two 250-mg tablets of magnesium oxide (MG) daily and the other receiving placebo (PG) for 8 wk. The Beck Depression Inventory-II was conducted and the concentration of serum magnesium was measured. RESULTS: At the end of intervention, 88.5% of the MG and 48.1% of the PG (P = 0.002) had a normal level of magnesium. The mean changes of serum magnesium were significantly different across the two groups. After the intervention, the mean Beck score significantly declined. However, in the MG, this reduction was more significant than in the PG (P = 0.02), so that the mean changes in this group experienced 15.65 ± 8.9 reduction, but in the PG, it declined by 10.40 ± 7.9. CONCLUSIONS: Daily consumption of 500 mg magnesium oxide tablets for ≥8 wk by depressedpatients suffering from magnesium deficiency leads to improvements in depression status and magnesium levels. Therefore, assessment of the magnesium serum and resolving this deficiency positively influence the treatment of depressedpatients.
Authors: Emily K Tarleton; Benjamin Littenberg; Charles D MacLean; Amanda G Kennedy; Christopher Daley Journal: PLoS One Date: 2017-06-27 Impact factor: 3.240
Authors: Markus S Anker; Stefan D Anker; Andrew J S Coats; Stephan von Haehling Journal: J Cachexia Sarcopenia Muscle Date: 2019-12 Impact factor: 12.910
Authors: Iwona Rotter; Adrian Wiatrak; Aleksandra Rył; Katarzyna Kotfis; Żaneta Ciosek; Maria Laszczyńska; Olimpia Sipak-Szmigiel; Aleksandra Szylińska Journal: Medicina (Kaunas) Date: 2020-03-13 Impact factor: 2.430